Buprenorphine/naloxone - one formulation that doesn't fit all: a case report.  Braun HM, Taylor JL, Axelrath S.  Harm Reduct J. 2024 Jul 30;21(1):143. doi: 10.1186/s12954-024-01054-2. PMID: 39080714; PMCID: PMC11287853. https://www.ncbi…

'Matters-of-concern' associated with discontinuation of long-acting injectable buprenorphine: Findings from a longitudinal qualitative study.  Parkin S, Neale J, Strang J.  Int J Drug Policy. 2024 Jun 5;129:104470. doi: 10.1016/j.drugpo…

Buprenorphine deaths confirmed by toxicology reveal a low proportion of opioid agonist treatment before death in Finland.  Mariottini C, Häkkinen M, Kriikku P, Ojanperä I. Int J Legal Med. 2024 Jun 24. doi: 10.1007/s00414-024-03273-5. Epub ah…

Low-dose overlap initiation with split tablets of buprenorphine in intubated intensive care unit patients with opioid use disorder.  Szczesniak L, Britton S, Rn TB, Sullivan R.  Harm Reduct J. 2024 Jun 7;21(1):114. doi: 10.1186/s12954-02…

Insomnia symptoms and neurofunctional correlates among adults receiving buprenorphine for opioid use disorder.  White AM, Eglovitch M, Parlier-Ahmad AB, Dzierzewski JM, James M, Bjork JM, et al. (2024)  PLoS ONE 19(6): e0304461. doi…

Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder.  Azar P, Schneiderman H, Barron H, Wong JSH, Meyer M, Newman-Azar D, Narimani M, Ignaszewski MJ, Mathew N, Mu…